A61K 47/6843
The antibody targeting a material from animals or humans
Official title: {the antibody targeting a material from animals or humans}
A61K47/6843 (The antibody targeting a material from animals or humans) appears on 418 US grants and 746 published applications in this corpus.
Search patents in A61K- Granted patents
- 418
- Published applications
- 746
- Assignees
- 354
- Inventors
- 1,479
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 5 | 0 |
| 1998 | 14 | 0 |
| 1999 | 4 | 0 |
| 2000 | 6 | 0 |
| 2001 | 5 | 1 |
| 2002 | 7 | 13 |
| 2003 | 7 | 15 |
| 2004 | 3 | 13 |
| 2005 | 1 | 13 |
| 2006 | 4 | 8 |
| 2007 | 6 | 25 |
| 2008 | 4 | 14 |
| 2009 | 7 | 34 |
| 2010 | 4 | 29 |
| 2011 | 10 | 20 |
| 2012 | 15 | 23 |
| 2013 | 6 | 18 |
| 2014 | 10 | 23 |
| 2015 | 33 | 31 |
| 2016 | 28 | 53 |
| 2017 | 23 | 36 |
| 2018 | 29 | 35 |
| 2019 | 32 | 39 |
| 2020 | 17 | 35 |
| 2021 | 20 | 42 |
| 2022 | 29 | 37 |
| 2023 | 20 | 52 |
| 2024 | 20 | 45 |
| 2025 | 28 | 51 |
| 2026 | 14 | 41 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment and/or diagnosis of a cancer type characterized by expressing zinc transporter ZIP415 Sep 2026US 12,734,245 B2Universitat Pompeu Fabra
- Antibodies recognizing tau15 Sep 2026US 12,735,507 B2Prothena Biosciences Limited
- Blood-brain barrier-penetrating nanotheranostics for acute and chronic neurodegenerative diseases and the like14 Jul 2026US 12,678,457 B2The Governing Council of the University of Toronto
- Method for the treatment or prophylaxis of cancer by targeting the extracellular portion of keratin 14 (KRT14) residing on cancer cells7 Jul 2026US 12,673,985 B2Hudson Institute of Medical Research
- Anti-EDB antibodies and antibody-drug conjugates16 Jun 2026US 12,653,901 B2Pfizer Inc.
- Antibody-drug conjucates employing novel linker-payload systems for enhanced targeting of cancer-associated glycan antigens8 Oct 2026US 2026/0306655 A1BioNTech SE
- Thrombin sensitive platelet like particles8 Oct 2026US 2026/0306660 A1North Carolina State University
- Composition comprising an antibody which binds to human srrm2 present on the cell surface of a target cell8 Oct 2026US 2026/0308237 A1Eximmium Biotechnologies GmbH
- Antibody targeting dll3 and use of antibody8 Oct 2026US 2026/0308240 A1Neukio Biotherapeutics (Shanghai) Co., Ltd.
- Humanised antibodies and uses thereof24 Sep 2026US 2026/0284244 A1Telix Pharmaceuticals (Innovations) Pty Ltd.
Most cited
By later US patents
- Therapeutic inhibitor of vascular smooth muscle cells562US 5,733,925 ANeoRx Corporation · 1998
- Therapeutic inhibitor of vascular smooth muscle cells438US 5,981,568 ANeoRx Corporation · 1999
- Monoclonal antibodies directed to the HER2 receptor435US 5,677,171 AGenentech, Inc. · 1997
- Therapeutic inhibitor of vascular smooth muscle cells308US 6,074,659 ANoeRx Corporation · 2000
- Therapeutic inhibitor of vascular smooth muscle cells280US 5,811,447 ANeoRx Corporation · 1998